Germany - Drugs

Description

§ Section 130a (8) of the German Social Code, Book V (SGB V) enables health insurance funds and pharmaceutical companies to conclude framework discount agreements for drugs to be dispensed at the expense of the statutory health insurance funds. With regard to the relevant legal regulations for the award of public contracts, a regular process of active substance-related, formal award procedures in accordance with the regulations of the 4th part of the GWB is carried out by DAK-Gesundheit. For drugs to be named by the bidder in more detail in Annex 2 to the contract for the above-mentioned active ingredient Rituximab, ATC L01AF01, DAK-Gesundheit intends to conclude drug rebate contracts with as many interested pharmaceutical companies as possible until new drug rebate contracts come into force.For the above-mentioned active ingredient, ARGE Rituximab III intends to conclude drug framework rebate contracts with as many, at least all, interested pharmaceutical companies as possible.The following health insurance companies are members of the ARGE Rituximab III:- DAK-Gesundheit- Techniker Krankenkasse- Kaufmännische Krankenkasse- HEK - Hanseatische Krankenkasse- Hkk - Handelskrankenkassetogether hereinafter referred to as "health insurance companies".A rebate contract in the context of the approval model for the above-mentioned active ingredient comes into force for the first time on 01.08.2023 and ends on 31.07.2025. Irrespective of this, it ends automatically when the exclusive contract comes into force.
The ARGE Rituximab III assumes that this procedure does not fall within the scope of antitrust procurement law due to the lack of a selection decision and thus the non-discriminatory access of all pharmaceutical companies. Irrespective of this, it ends automatically with the entry into force of the exclusive contract for rituximab, ATC L01AF01, as a result of a formal award procedure in accordance with the regulations of Part 4 of the ARC with one or more contract partners. In order to do justice to the diversity of potential contractual partners within the framework of the approval model, each pharmaceutical company will be enabled to conclude a framework agreement at any time and under the same conditions during the term of the agreement. The contract documents required for this purpose are available for download via the online portal www.dtvp.de/center under the link mentioned under I.3.Prerequisites for concluding, or later joining, the contracts that will come into force for the first time on 01.08.2023 are the complete and timely submission of the following documents (available for download under the link mentioned under I.3) to the following department at DAK-Gesundheit:1. Letter of offer2. Acknowledgement of the contractual requirements of DAK-Gesundheit, in particular also of the specified discounts, by submission of the contract with name or company stamp by the interested party at the designated place.3. The completed attachments 1 and 2 to the contract. The interested party must enter here the drugs for the above-mentioned active ingredient which are to be the subject of the contract.The documents are to be submitted PER e-mail bei:openhouse@dak.deDAK-GesundheitFachbereich Arzneimittel (0038 00)Nagelsweg 27-3120097 HamburgAnnex 2 is to be sent expressly as an Excel file to the e-mail address openhouse@dak.de.Contracts under this model and for the above-mentioned active ingredient will be concluded for the first time with effect from 01.08.2023 and will end on 31.07.2025.Interested parties who wish to become contractual partners on this date must submit the above-mentioned, documents to be submitted to the above-mentioned office by 01.07.2023. To meet the deadline, electronic receipt of the complete documents by e-mail to the e-mail address openhouse@dak.de is sufficient. The offer must be submitted in text form as an electronic offer PER E-MAIL to openhouse@dak.de. The offer must be submitted by post. Submission of the bid by mail is not intended in this procedure.Please do NOT submit the bid via the German Procurement Portal.To meet the deadline, electronic receipt of the complete documents PER E-MAIL to the e-mail address openhouse@dak.de is sufficient.Subsequent accessions are possible at any time. In order to be able to join during the term of the contract on the 1st or 15th of the following month, the above-mentioned documents must be received by DAK-Gesundheit by the 5th of the previous month, irrespective of the desired accession. Here, too, timely receipt by e-mail at DAK-G is decisive. Example: The bidder's desired date of entry is 15.07.20xx (following month), the documents must be received by 05.06.20xx (preceding month). As already made clear, this is not one of those - the announcement had to be used for technical reasons, as there is no form suitable for admission procedures.

Opportunity closing date

05 June 2025

Value of contract

£0-100k